Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus investigator-selected chemotherapy for advanced HER2-negative breast cancer (multicohort, single-arm)
ChiCTR2500110355Phase 4Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Oct 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of toripalimab in breast cancer and triple-negative breast cancer (TNBC) (3 cohorts), sponsored by Henan Cancer Hospital. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
breast cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2500110355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110355.